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Variant p.(Arg118Cys)Lysosomal α-galactosidase A (α-Gal) is the enzyme deﬁcient in Fabry disease (FD), an X-linked glycosphingo-
lipidosis caused by pathogenic mutations affecting the GLA gene. The early-onset, multi-systemic FD classical
phenotype is associated with absent or severe enzyme deﬁciency, as measured by in vitro assays, but patients
with higher levels of residual α-Gal activity may have later-onset, more organ-restricted clinical presentations.
A change in the codon 118 of the wild-type α-Gal sequence, replacing basic arginine by a potentially sulfhydryl-
binding cysteine residue – GLA p.(Arg118Cys) –, has been recurrently described in large FD screening studies of
high-risk patients. Although the Cys118 allele is associated with high residual α-Gal activity in vitro, it has been
classiﬁed as a pathogenic mutation, mainly on the basis of theoretical arguments about the chemistry of the
cysteine residue. However its pathogenicity has never been convincingly demonstrated by pathology criteria.
We reviewed the clinical, biochemical and histopathology data obtained from 22 individuals of Portuguese and
Spanish ancestry carrying the Cys118 allele, including 3 homozygous females. Cases were identiﬁed either on
the differential diagnosis of possible FD manifestations and on case-ﬁnding studies (n = 11; 4 males), or on
unbiased cascade screening of probands' close relatives (n = 11; 3 males). Overall, those data strongly suggest
that the GLA p.(Arg118Cys) variant does not segregate with FD clinical phenotypes in a Mendelian fashion, but
might be amodulator of themultifactorial risk of cerebrovascular disease. The Cys118 allelic frequency in healthy
Portuguese adults (n = 696) has been estimated as 0.001, therefore not qualifying for “rare” condition.
© 2014 Elsevier Inc. All rights reserved.Faculdade de Medicina, Universidade do Porto, Alameda Hernâni Monteiro, 4200-319 Porto, Portugal. Fax: +351 225513648.
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List of GLA gene mutations in amino acid positions where mutations to cysteine have also
been reported.
Amino acid
residue position
Wild-type
amino acid
Clinical phenotype of
mutation to cysteine
Described mutations
other than to cysteine
112 Arg Classical His(a)/Ser
162 Trp Classical Arg
171 Gly Classical Arg/Asp
216 Tyr Classical Asp
226 Trp Unknown(b) Arg
235 Ser Classical Phe
236 Trp Classical Arg/Leu
271 Gly Classical Ser/Val
287 Trp Classical Gly
297 Ser Classical Phe
360 Gly Classical Asp/Ser
363 Arg Classical His
Amino acid positions in theα-galactosidaseAmonomer are sequentially counted from the
methionine residue coded by themRNA start codonwhich, by convention, is numbered as
position 1.
Amino acid names are abbreviated according to the three-letter code: Arg = arginine;
Asp = aspartate; Cys = cysteine; Gly = glycine; His = histidine; Leu = leucine;
Phe = phenylalanine; Ser = serine; Trp = tryptophan; Tyr = tyrosine; Val = valine.
(a) Mutation p.(Arg112His) has been consistently associated with late-onset cardiac
variant of Fabry disease.
(b) Mutation p.(Trp226Cys) was identiﬁed in a 16-year-old boy with the classical phe-
notype of Fabry disease, segregating in ciswith mutation p.(Arg227Ter); as this nonsense
mutation is known to cause a severe deﬁciency of α-galactosidase A activity, leading to
classic Fabry disease, the intrinsic severity of the cysteine mutation has not been deﬁned.Alpha-galactosidase A (α-Gal; EC 3.2.1.22), the lysosomal hydrolase
deﬁcient in Fabry disease (FD, OMIM #301500), is a homodimeric gly-
coprotein encoded by the GLA gene, which is located on the long arm
of the X chromosome [1–3]. Decreased α-Gal activity in humans leads
to accumulation of neutral glycosphingolipids (GSL) with terminal α-
galactosyl residues, predominantly globotriaosylceramide (Gb3 or GL-
3), in many different types of cells and in body ﬂuids. The severity of
the clinical phenotype in affected males is broadly related to residual
α-Gal activity: the lower the enzyme activity, the earlier is the age of
onset, and more severe and multi-systemic are the clinical manifesta-
tions. In classic FD, caused by complete absence or marked deﬁciency
of α-Gal activity, the vascular endothelium and smooth muscle cells,
the peripheral and autonomic nervous systems, the kidneys, the heart
and the brain are major sites of pathology, and the affected males usu-
ally become symptomatic during childhood or adolescence [1,3]. In
patients with higher levels of residualα-Gal activity, the resultant phe-
notypes are more organ-restricted, usually to the heart, and have a
much later clinical onset, frequently in mid-adulthood [3]. Like other
X-linked genetic disorders, males with FD are more severely affected
than females,many ofwhomhave limited organ involvement or remain
asymptomatic, although a fewmay in rare instances express the severe
phenotype of the disease [4].
More than 750 different pathogenic GLA mutations are reported in
“The Human Gene Mutation Database (HGMD®)” [http://www.hgmd.
cf.ac.uk/ac/gene.php?gene=GLA, last accessed on August 1, 2014], of
which about 2/3 are missense or nonsense point mutations. Most of
the pathogenic GLAmutations are private to single families [5].
The mature α-Gal monomers have 12 cysteine (Cys) residues, at
positions 52, 56, 63, 90, 94, 142, 172, 174, 202, 223, 378, and 382 in
the polypeptide chain [2]. Five disulﬁde bonds, between cysteine resi-
dues at positions 52–94, 56–63, 142–172, 202–223 and 378–382, are
important for the stabilization of the three-dimensional structure of
the enzyme; furthermore, the 142–172 disulﬁde contributes to the α-
Gal catalytic site. The Cys90 and Cys174 residues are unpaired. An addi-
tional cysteine (Cys12) is removed from the monomer during the post-
translational enzyme maturation, as part of the signal peptide.
Missense mutations affecting any one of the cysteines that form
the disulﬁde bonds of the wild-type α-Gal structure are associated
with the classic FD phenotype, and show negligible or very low resid-
ual enzyme activity [6–24], attesting their importance for normal en-
zyme function. Missense mutations involving the Cys12 or Cys90
residues have never been reported in FD patients. So far, two mis-
sense variants have been described that affect GLA Cys174, respec-
tively changing the wild-type cysteine to arginine (Arg) or glycine
(Gly) [http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA, http://
www.genomed.org/lovd2/variants.php?select_db=GLA&action=
view_all, last accessed on August 1, 2014]. While mutation
p.(Cys174Arg) is reportedly associated with classic FD [25],
p.(Cys174Gly) is still classiﬁed as a single nucleotide polymorphism
(SNP) at the Short Genetic Variations database (dbSNP) of the Na-
tional Center for Biotechnology Information [NCBI; National Library
of Medicine, Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov/
projects/SNP/snp_ref.cgi?rs=181562693, last accessed on August
1, 2014]. However, GLA p.(Cys174Gly) has recently been identiﬁed
in a patient presenting with an unusual late-onset renal variant of
FD [26], raising doubts about its clinical benignity [27].
Several missense mutations that introduce an extra cysteine into
the amino acid sequence ofα-Gal have been identiﬁed in FD patients.
As the additional thiol can interfere with the correct formation of the
5 disulﬁde bonds critical to the α-Gal structure, such mutations are
theoretically severe and expected to lead to classic FD. However, by
comparison with mutations substituting other amino acids at the
same positions (Table 1), it seems more likely that the functional
impact of these mutations depends more on their location on thethree-dimensional structure of the protein than on the speciﬁc
amino acid change.
A cysteine-involving GLA SNP variant of uncertain pathogenicity
(allelic variant of uncertain signiﬁcance, VUS) results from the cyto-
sine to thymine transition (CNT) at a CpG dinucleotide in codon 118
(c.352CNT), leading to the non-conservative replacement of a basic
arginine in the wild-type α-Gal sequence by an uncharged polar,
sulfhydryl-containing, cysteine residue — p.(Arg118Cys), or
p.R118C in the single letter code. This SNP was originally identiﬁed
in a Portuguese family [Oliveira JP, poster presentation; 5th
European Round Table on Fabry Disease, 2004], but its ﬁrst descrip-
tion in a peer-reviewed article was with the results of a large-scale
Italian newborn screening of FD, published in 2006 [28]. Subse-
quently, the GLA p.(Arg118Cys) variant was recurrently identiﬁed
in large FD case-ﬁnding studies among patients with stroke, left ven-
tricular hypertrophy (LVH) or on chronic dialysis, carried out in dif-
ferent European populations [29–32] (summarized in Table 2) and in
Brazil [33].
Molecular modeling (Fig. 1) showed that GLA Cys118 does not
alter the active site of the enzyme, therefore not interfering with its
catalytic mechanism, and can be accommodated within the crystal
structure of the α-Gal protein [28]. These data are comparable to
those of other GLA mutations associated with later-onset FD pheno-
types and led to the prediction that the α-Gal p.(Arg118Cys) might
have altered stability, making it a potential candidate for rescue by
pharmacological chaperones. In COS-7 cells transiently transfected
with a mutant GLA Cys118 cDNA construct, the intracellular α-Gal
residual activity was 29% of the mean transiently expressed Arg118
wild-type activity, increasing 1.1 fold following incubation with the
chaperone deoxygalactonojirimycin (DGJ) [28]. Notably, the α-Gal
p.Arg118Cys response to incubation with DGJ was several orders of
magnitude lower than structurally similar GLAmutations andmerely
5% more than the wild-type enzyme.
At the dbSNP, GLA c.352CNT is identiﬁed as a single nucleotide
variation of uncertain clinical signiﬁcance [http://www.ncbi.nlm.nih.
gov/projects/SNP/snp_ref.cgi?rs=148158093, last accessed on August
1, 2014], with conﬂicting clinical data provided by different submitters.
Table 2
Summary of the large Fabry disease case-ﬁnding studies among high-risk patient populations which have identiﬁed individuals carrying the GLA p.(Arg118Cys) sequence variant.
Study Location Disease screened and patient
enrollment conditions
Cohort size and
demographic features
Screening method Cases found Reference
(year)
“Screening genetic conditions in Portuguese young stroke patients — PORTYSTROKE”
Portugal Stroke
Age range: 18–55 y
(ﬁrst stroke, incident,
unselected)
493
[M: 300 (61%)/F: 193 (39%)]
Mean age: 45y
Direct sequencing of PCR or RT-PCR products 6
M: 46 y, 45 y, 42 y F: 40 y,
39 y, 33 y
[29]
2010
Screening for Fabry disease among patients undergoing hemodialysis in Spain
Spain ESRD/HD
(prevalent, unselected)
911
[M: 543 (60%)/F: 368 (40%)]
Mean ages: M = 66 y/
F = 67 y
DBS α-Gal assay; cut-off for genetic analyses: M
b48%(N)/F b80%(N)
→ DHPLC/GLA variants conﬁrmed on direct
sequencing of PCR products
4
M: 83 y, 72 y
F: 50 y, 47 y
[30]
2010
“European Anderson–Fabry Disease survey”
Europe Unexplained LVH (LVWT
≥15 mm)
Age: M N 35y/F N 40 y
(prevalent)
1386
[M: 886 (64%)/F: 500 (36%)]
Mean age: 58 y
DHPLC/GLA variants conﬁrmed on direct
sequencing of PCR products
1
F: 45 y
[31]
2011
“Stroke in young Fabry patients — SIFAP”
Europe Stroke
Age range: 18–55 y
(incident, unselected)
5023
[M: 2962 (59%)/F: 2061 (41%)]
Median age: 46 y
Direct sequencing of PCR products 1 (*) [32]
2013
GLA: α-galactosidase A gene; α-Gal: α-galactosidase A.
ESRD/HD: end-stage renal disease on hemodialysis. LVH: left ventricular hypertrophy; LVWT: left ventricular wall thickness.
M: male/F: female; y: age in years. (*) presumably only one case, but no demographic or clinical details were reported.
PCR: polymerase chain reaction; RT-PCR: reverse transcription polymerase chain reaction. DHPLC: denaturing high-performance liquid chromatography, used for ﬁrst-tier rapidmutation
screening. DBS: dried blood spot on ﬁlter paper. %(N): percent of the normal mean.
Fig. 1.Molecular structure of the wild-type mature human α-galactosidase A enzyme and modeling of the p.(Arg118Cys) variant: the change to cysteine is easily accommodated in the
three-dimensional structure of the enzyme because the arginine is a surface residue and there is plenty of room to substitute the cysteine side chain. However, the cysteine side chain has
different chemistry, which can interfere with the correct folding of the disulﬁde bonds required for the structure, or it could interfere with the binding of other molecules – like the chap-
erones BiP (binding immunoglobulin protein) and calnexin−, that are required for the folding and trafﬁcking of theα-galactosidase A the lysosome. The structural prediction is that the
protein should be active when it folds, but the efﬁciency of folding and trafﬁcking will be reduced. This is consistent with the results of in vitro overexpression experiments [28].
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estimated as 0.001 [https://esp.gs.washington.edu]. On bioinformatic
analyseswith different software packages,GLAp.Arg118Cys is predicted
to be a “polymorphism” by MutationTaster [http://www.mutationtaster.
org/], “benign” by PolyPhen-2 [http://genetics.bwh.harvard.edu/pph2/]
and “deleterious” by SIFT [http://sift.jcvi.org/], whereas Panther scores
[http://www.pantherdb.org/tools/csnpScore.do] are marginally sugges-
tive that it may have a deleterious effect on protein function. It is of
note that another mutation at the same codon, leading to the replace-
ment of arginine by histidine (His), p.(Arg118His), is uniformly predicted
to be non-pathogenic.
Because of the ascertainment bias inherent to genetic screenings of
high-risk patient cohorts, cascade family studies and careful clinical
evaluation of unbiasedly diagnosed subjects are an important approach
for the elucidation of the actual contribution of VUS to human disease.
Herein,we report the clinical phenotypes observed in a series of individ-
uals and families of Iberian (Portuguese and Spanish) ancestry carrying
the GLA Cys118 allele, and genetic epidemiology data collected in the
Portuguese population.Fig. 2. a. Detail of the eruption of angiokeratomas observed in a 26-year-old woman
heterozygous for the GLA p.(Arg118Cys) sequence variant. The angiokeratomas localized
exclusively to the buttocks and proximal thighs and had a symmetrical distribution. This
patient was the proband of the ﬁrst Portuguese family in whom the GLA p.(Arg118Cys)
variant was identiﬁed. b. Light-microscopy histopathology of the skin biopsy obtained
from that patient. There is subepidermal proliferation of telangiectatic vessels lined by
thin endothelial cells and surrounded by collarettes of thickened rete ridges. The dilated
vascular spaces areﬁlledwith blood or thrombosed. The corneal layer ismoderately thick-
ened, showing mild parakeratosis.2. Patients, materials and methods
Portuguese and Spanish individuals carrying the GLA Cys118 var-
iant allele, as well as a Portuguese family emigrated in France, were
identiﬁed either (i) on the differential diagnostic workup of individ-
ual patients presenting with possible clinical manifestations of FD;
(ii) on systematic screenings of large cohorts of patients at high-
risk for FD carried out in Portugal and Spain; and (iii) on cascade
genetic screening of probands' close relatives (including a patient
identiﬁed through screening for FD in a cohort of patients with
hypertrophic cardiomyopathies in France). The relevant demo-
graphic, clinical, laboratory and imaging data were retrospectively
collected by systematic review of existingmedical records. Particular
attention was speciﬁcally paid to possible manifestations of FD,
including dermatological (e.g., hypohidrosis, angiokeratomas), neu-
ropathic (e.g., acroparesthesias), ophthalmological (e.g., cornea
verticillata, conjunctival and retinal vascular abnormalities), cere-
brovascular (e.g. transient ischemic attack, stroke, brain imaging
abnormalities), cardiac (e.g., arrhythmias, LVH, ischemic heart
disease) and renal (e.g., proteinuria, azotemia). Representative
pathology illustrations were prepared from archive tissue biopsies
and electron micrographs.
PlasmaGb3 concentrationwas estimated by a densitometricmethod,
following thin-layer chromatography separation. To determine the Gb3/
sphingomyelin molar ratio in the urinary sediment, Gb3 and sphingo-
myelin were quantiﬁed densitometrically after high-performance thin-
layer chromatography, in centrifuged urine samples. Urinary Gb3 was
measured by high-performance liquid chromatography (LC) coupled to
tandem mass spectrometry (MS/MS), and lyso-Gb3 in plasma and
urine samplesweremeasured by ultra-performance LC-MS/MS,working
in positive electrospray ionization mode.
TheDXS8020,DXS8034, DXS8089, DXS8063 andDXS8096microsat-
ellite sequence-tagged sites (STS), spanning ≈ 3 cM around the GLA
gene, were used for haplotyping. Brieﬂy, the relevant STS were ampli-
ﬁed in two multiplex polymerase chain reactions (PCRs) with 6-
FAMTM ﬂuorescent dye-labeled forward primers (Thermo Fisher Scien-
tiﬁc; Waltham, MA, USA), according to their annealing temperatures,
and the corresponding PCR amplicons were analyzed with an ABI
3500 Genetic Analyzer (Applied Biosystems, Life Technologies; Foster
City, CA, USA), using the GeneMapper® software version 4.1 (Applied
Biosystems).
A commercial multiplex-ligation probe ampliﬁcation kit (SALSA
MLPA P159-A3 GLA probemix; MRC-Holland; Amsterdam, the
Netherlands) was used to screen for GLA gene duplications/deletions
in females carrying the GLA Cys118 allele in apparent homozygosity.Statistical analyses were carried out with GraphPad Prism, version
5.0 (GraphPad Software, Inc.; La Jolla, CA, USA).3. Results
3.1. Clinical data from the original patient and family
We have ﬁrst identiﬁed GLA p.(Arg118Cys) on the genetic work-
up of a 26-year-old female who had been referred to the Dermatol-
ogy clinic with an extensive, symmetrically distributed eruption of
angiokeratomas in the buttocks and proximal thighs (Fig. 2a), that
she reported to have initially noticed four years before (clinical de-
tails published elsewhere) [34]. The clinical diagnosis of Fabry
angiokeratomas was further supported by the light-microscopy
(LM) ﬁndings on a biopsy of the affected skin (Fig. 2b). The α-Gal
A activity was within the normal control values, both in leukocytes
(44 nmol/h/mg; normal range: 36–80) and in plasma (12.8 nmol/h/ml;
normal range: 6.2–19.4), but the Gb3 concentration was slightly
elevated in plasma (15.02 μg/ml; normal range: 0.67–10.66).
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resistant nephrotic syndrome but she had remained normotensive,
her serum creatinine (sCr) was within the normal (0.68 mg/dl) and
examination of the urine sedimentwas unremarkable. The kidney ultra-
sound scan showed no abnormalities. The patient speciﬁcally denied
past history or any current symptoms of neuropathic involvement, of
abnormal sweating, and of cardiac or cerebrovascular disease. Slit-
lamp ophthalmological examination did not reveal the corneal dystro-
phy or the conjunctival and retinal microvascular lesions typical of
classical FD. The electrocardiogram (ECG) showed incomplete right
bundle branch block (RBBB) but the echocardiogram was normal.
At age 13 years, the diagnostic workup for causes of secondary
nephrotic syndrome had been negative. The kidney biopsy disclosed a
mesangial proliferative glomerulonephritis, with no immune deposits
visible on immunoﬂuorescence microscopy. The baseline glomerular
ultrastructural pathology could not be examined due to the lack of
glomeruli on the sample processed for electron microscopy (EM)
study. Since the nephrotic syndrome did not respond to standard
immunosuppressive protocols, non-speciﬁc treatment with an angio-
tensin converting enzyme inhibitor (ACEi), with dose titrated according
to proteinuria.
Considering the possibility of having missed the diagnosis of FD ne-
phropathy on the LM examination of the ﬁrst kidney biopsy, and the
theoretical hypothesis of unilateral or focal kidney involvement, Gb3/
sphingomyelin concentration ratio was measured in a voided bladder
urine specimen and in specimens collected from each of the ureters,
with no evidence of increased urinary Gb3 excretion (bladder b 0.01,
left kidney b 0.01, right kidney= 0.04; normal controls b 0.3). A second
kidney biopsy was eventually obtained at age 29 years, from the right
kidney. On LM examination, the renal pathology was similar to that
described in the ﬁrst biopsy. In addition, the toluidine blue-stained
semi-thin scout sections for EM did not show any GSL inclusions, and
no “myelin ﬁgure” and/or “zebra body” deposits that might be sugges-
tive of FD nephropathy could be identiﬁed on the ultrastructural exam-
ination. On retrospective immunohistochemical study of this kidney
biopsy with a murine anti-Gb3 antibody, Gb3 immunoreactivity was
identiﬁed only in a few tubular cells, which is a staining pattern similar
to that observed in the kidney tissue of control subjects [35]. At age 37
years, the plasma lyso-Gb3 and the urinary Gb3 levels remained within
normal range.
Family screening showed the patient had inherited the GLA Cys118
allele from her father and that none of her father's two brothers and
two sisters who were still alive and accepted to be genotyped carried
the variant allele; two of her father's sisters had died during childhood
and an older brother had died in his early eighties. Neither of these,
nor the remaining brother who was not genotyped, had any clinical
manifestations of FD. The proband's paternal grandmother had died in
the late 8th decade, possibly from complications of type 2 diabetes
mellitus (DM2). Four of the proband's 5 living paternal uncles and
aunts, as well as her grandfather, also had history of DM2.
The proband's father was initially evaluated at age 55 years and
reported the following major medical problems: (i) DM2 diagnosed at
age 39 years; (ii) hypertension, on treatment with an ACEi since age
51 years; (iii) mild mixed hyperlipidemia; (iv) long-lasting history of
chronic alcohol abuse, with alcoholic liver disease conﬁrmed on a liver
biopsy at age 51 years; (v) bilateral carpal tunnel syndrome, conﬁrmed
on electromyography. He also had history of sinus bradycardia, ﬁrst
detected on a routine ECG obtained at age 40 years. About 5 years
later he was evaluated at the cardiology clinic for the persistence of
sinus bradycardia and newly diagnosed complete RBBB, but was even-
tually discharged because no evidence of an underlying cardiac pathol-
ogy could be found.
An echocardiographic study performed at age 56 years showedmild
LVH, with interventricular septal thickness of 13mm and posterior wall
thickness of 12 mm, and with a transvalvular mitral ﬂow pattern
suggestive of diastolic dysfunction. Results of exercise stress ECG testingand 24-hour continuous ambulatory ECG monitoring were unremark-
able. A cardiac biopsy was obtained for differential diagnosis of LVH:
although themyocardial tissue appeared histologically normal, without
hypertrophy or vacuolization of cardiomyocytes andwith no interstitial
ﬁbrosis, the EM examination showed small myelin ﬁgures within
rare cardiomyocytes (Fig. 3). Hehadnohistory of clinicalmanifestations
of classical FD, including angiokeratomas, childhood-onset acropar-
esthesias or hypohidrosis, and the slit-lamp ophthalmological examina-
tion was normal. His baseline sCr was normal (0.79 mg/dl), the
urinalysis did not show proteinuria or abnormalities of the urinary
sediment, and a kidney ultrasound scan was unremarkable. The α-Gal
activity was within the low-normal range, both in leukocytes (25
nmol/h/mg; normal range: 22–73) and in plasma (3 nmol/h/ml; normal
range: 2.0–21.0). The plasma lyso-Gb3 and the urinary Gb3 levels,
measured at age 64 years, were within the normal range.
Along 10 years of follow-up, neither the proband nor her father had
any major clinical events attributable to FD, or evidence of cardiac or
renal disease progression. On ACEi treatment, the proband's urinary
albumin excretion has been maintained b250 mg/g[creatinine]. At the
age of 34 years, two small hyperintense foci were visible at left fron-
tal subcortical and right subinsular locations, on a brain magnetic
resonance imaging (MRI). Her father's brain MRI, obtained at age
61 years, showed multiple hyperintense white matter lesions (WML)
located to the periventricular area, and in the corona radiata and
centrum semiovale.
3.2. Clinical data from the PORTYSTROKE study
Three males and three females carrying the GLA Cys118 allele were
identiﬁed in the PORTYSTROKE study [29] (Table 2). The mutation
screening method in the Portuguese study was by genotyping, and the
plasma and leukocyte α-Gal activities were measured as a second step
in all patients who carried a GLA gene variant. This was a major differ-
ence in comparison to other previous or contemporary large case-
ﬁnding studies carried out in southern European countries, either in
non-selected male neonates [28] or in high-risk patient series [30],
that have also identiﬁed individuals carrying the p.(Arg118Cys) variant,
because the latter have used the αGal activity measured in dried blood
spots (DBS) on ﬁlter paper as the screening assay, and only those cases
with residual enzyme activity below a predeﬁned cut-off level were
subsequently genotyped.
The demographic and clinical features of the 6 patients carrying the
Cys118 alelle, and the corresponding results of the α-Gal assays in
leukocytes and plasma, are summarized in Fig. 4. The average residual
leukocyte and plasmaα-Gal activities inmales and femaleswere, respec-
tively, 18.7 nmol/h/mg (32% of the control mean) and 7.3 nmol/h/ml
(58% of the control mean), and 33.7 nmol/h/mg (58% of the control
mean) and 8.4 nmol/h/ml (67% of the control mean). Interestingly, the
female with the lowest residual leukocyteα-Gal activity (corresponding
to ≈60% of the average activity of the other two females) carried
the g.1170CNT/c.–10CNT SNP of the GLA 5′-untranslated region (5′
UTR), which is known to be associated with lower α-Gal activity levels
in leukocytes [36,37].
All the males had multiple major cardiovascular risk factors. The
youngest of them, who had DM2 and presented mild proteinuria,
underwent a kidney biopsy to exclude Fabry nephropathy: LM exami-
nation was diagnostic of diabetic nephropathy and the EM study did
not show any typical GSL inclusions (Fig. 5). None of the three male
probands showed LVH on echocardiographic examination. None of the
patients had family history suggestive of FD but the two females
presenting with ischemic stroke had family histories of stroke.
Three of the families were referred for genetic screening of the
proband's living ﬁrst-degree relatives. Maternal inheritance was
conﬁrmed in the two families where the proband's parents were
available for genotyping: the two transmitting mothers of the GLA
Cys118 allele were in good health, respectively at ages 70 and 69 years,
Fig. 3. a. Light microscopy of an endomyocardial biopsy taken from the right ventricle of a 56-year-old man hemizygous for the GLA p.(Arg118Cys) sequence variant. None of the typical
features of Fabry disease cardiomyopathy – e.g. cardiomyocyte hypertrophy or vacuolation, enlarged nuclei or ﬁber branching and disarray –, are observed in this section. b. An electron
microphotograph of the endomyocardial biopsy of the same patient also does not show any cardiomyocyte inclusions typical of Fabry disease, i.e.with the ultrastructural morphology of
“zebra body” or “myelin ﬁgure”.
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trocardiographic or echocardiographic abnormalities or laboratory
evidence of kidney involvement.3.2.1. Post-hoc epidemiological analyses of the PORTYSTROKE patient
cohort
By screening DNA samples of 360 males and 336 females, aged
18–45 years, from healthy cohorts of volunteermedical students, fertile
males and bonemarrowdonors, the 95% conﬁdence interval (95%CI) for
the allelic frequency of GLA Cys118 in the general Portuguese popula-
tionwas estimated between b0.0001–0.006. As compared to the control
population, the allelic frequency of the GLA Cys118 allele was signiﬁ-
cantly higher among the stroke patients, irrespective of gender
(=0.0087, 95%CI: 0.004–0.019; Fisher's exact test, p = 0.0185).
However, when the PORTYSTROKE patients aged 45 years or less
(n = 204; 118 males) were entered as cases in a pair-matched case–
control analysis, with healthy adult bone marrow donors used as
gender- and age-matched controls, the estimated odds ratio (OR) for
the risk of stroke among carriers of GLA Cys118 did not reach statistical
signiﬁcance (OR = 5.0, 95%CI: 0.56–236.5; McNemar's test, p = 0.22).
Remarkably, the frequency of theGLA c.937GNT SNP, that causes the
replacement of aspartic acid (Asp) by tyrosine (Tyr) in codon 313 – i.e.,
p.(Asp313Tyr) or D313Y, which has been characterized as a non-
pathogenic allele, causing a “pseudodeﬁciency” ofα-Gal activity in plas-
ma [21] –, was signiﬁcantly higher among male stroke patients than in
controls (≈0.009 versus≈0.002; Fisher's exact test, p = 0.026). Also
of note is the observation that the minor allelic frequencies (MAF) of
GLA p.(Arg118Cys) and p.(Asp313Tyr) in the general Portuguesepopulation did not signiﬁcantly differ (1/1032 versus 2/1032; Fisher's
exact test, p = 1.0).
3.3. Clinical study of a Portuguese family emigrated in France
An asymptomatic 54-year-old male of Portuguese ancestry was
serendipitously found to carry the GLA Cys118 allele, on cascade screen-
ing of ﬁrst-degree relatives of a 59-year-old male diagnosed with FD-
associated hypertrophic cardiomyopathy (HCM). The proband had
been identiﬁed in a French case-ﬁnding study of incident patients
with LVHof unknown cause [38], usingDBSα-Gal activity as the screen-
ingmethod, andwas subsequently shown to be hemizygous for the GLA
mutation c.337TNC, that changes the translation of codon 113 from
phenylalanine (Phe) to leucine (Leu) – i.e., p.(Phe113Leu) –, known to
be associated with the cardiac variant of FD [2]. Genotyping of a
proband's younger brother, presenting the unusual value of 45% residu-
al α-Gal activity in the leukocyte enzyme assay, unexpectedly revealed
that he did not carry the p.(Phe113Leu) mutation but instead was
hemizygous for of the GLA p.(Arg118Cys) variant.
This individual reported no past medical history or current symp-
toms of FD. On physical examination, there were no angiokeratomas
or cornea verticillata. The sCr level was within the normal range, with
an estimated glomerular ﬁltration rate (GFR) of 96 ml/min/1.73 m2
[CKD-EPI equation; http://www.kidney.org/professionals/kdoqi/gfr_
calculator.cfm], and the urinalysis did not reveal any abnormalities.
Additional investigations included brain MRI, which did not show
hyperintense WML, lacunar infarctions or dolichoectasia of intracranial
arteries; cardiacMRI, which showed a left ventricle of normal thickness,
both at the posterior wall (7mm) and interventricular septum (9mm);
Fig. 4. Demographic and clinical features of the 6 stroke patients carrying the GLA p.(Arg118Cys) sequence variant that were identiﬁed in the PORTYSTROKE study, together with corre-
sponding results of α-galactosidase A assays in leukocytes and plasma. The pink and light-blue background areas are the normal reference ranges, respectively for the leukocyte and the
plasmaα-galactosidase A assays. The numbers of major risk factors for stroke that coexisted in each patient are presented as follows: hypertension, hyperlipidemia, diabetesmellitus and
smoking are summed up before and alcohol consumption and oral contraception are summed up after the plus sign. CVT: cerebral venous thrombosis.
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for age (84 ml/min/1.73 m2). On the basis of this diagnostic workup, it
was decided not to start enzyme replacement therapy.
The mother of both individuals, who most probably was an obligate
compound heterozygote p.(Phe113Leu)/p.(Arg118Cys), has recentlyFig. 5. Electronmicrograph of the kidney biopsy of a 42-year-oldmanwith type 2 diabetes
mellitus, hemizygous for the GLA p.(Arg118Cys) sequence variant, identiﬁed in the
PORTYSTROKE study. The patient presented with mild proteinuria and a kidney biopsy
was obtained for the differential diagnosis with diabetic nephropathy. Light-microscopy
examination was diagnostic of diabetic nephropathy and the electron microscopy study
did not show any intracellular inclusions with the “zebra body” or “myelin ﬁgure”mor-
phology, typical of Fabry disease nephropathy.passed away at the age of 87 years, in the absence of signiﬁcant health
problems that might be related to α-Gal deﬁciency.
3.4. The Spanish cohort
The demographic, genetic and clinical features observed in 11 indi-
viduals carrying the GLA p.(Arg118Cys) variant, belonging to 4 appar-
ently unrelated Spanish families, are summarized in Table 3. All 4
probands, who were aged between 50 and 82 years, were ascertained
on FD screening as a possible cause for left ventricular hypertrophy; re-
markably, only one of the probands was amale. In two families, cascade
genetic screening led to the identiﬁcation of one male and 6 females in
three consecutive generations, who also carried the GLA Cys118 allele.
None of these unbiasedly ascertained individuals manifested LVH, pro-
teinuric chronic kidney disease or any other signs or symptoms that,
at their age group, might be unequivocally attributable to α-Gal deﬁ-
ciency. Three related women were Cys118/Cys118 homozygotes. Two
sisters, respectively aged 60 and 51 years and the third was a cousin,
aged 67. The older of the two sisters was started on enzyme replace-
ment therapy following the abnormal result of the 24-hour Holtermon-
itoring and the ﬁnding of WML on brain MRI. In the homozygote
females, the residual α-Gal activity on the DBS assay ranged between
25–33% of the normal average.
3.5. Microsatellite haplotyping studies in Portuguese individuals
Themicrosatellite haplotypes segregatingwith theGLAp.(Arg118Cys)
allele were determined in 5 males and three females from apparent-
ly unrelated Portuguese families. Five different Cys118 haplotypes
were identiﬁed in the 8 chromosomes, suggesting that the CNT
Table 3
Demographic, genetic and clinical features observed in Spanish individuals carrying the GLA p.(Arg118Cys) variant.
Family
tree
entry
Gender/
age
(Y)
α-Gal
activity
GLA gene CNS Heart Kidney Eye Other symptoms and
comorbidities
(% normal)
DBS/plasma
R118C 5′
UTR
Brain MRI LVH IVS
(mm)
echo/
MRI
Holter
monitoring
sCr /
eGFR
UACR
(mg/g)
Family 1
F1:P
(II:1)
M/51 38/ND + WT Normal Yes 15/14 SVPB 0.8/
103
11 Normal No.
(I:2) F/81 77/83 +/− WT ND NA ND/
ND
ND 0.93/
58
2.8 Cataracts Primary biliary cirrhosis.
(II:3) F/48 69/39 +/− WT Normal No 9/8 Normal 0.8/
87
4 NA Hypohidrosis. Goiter.
Hypercholesterolemia.
(III:4) F/15 64/74 +/− WT ND NA ND/
ND
ND 0.7/
130
1.9 NA
Family 2
F2:P F/50 50/46 +/− WT ND Yes 18/15 SVT 1.2/
53
486.3 NA Angiokeratoma. Hypertension.
Family 3
F3:P
(II:1)
F/55 100/37 +/− WT Normal No 8/
15.5
Normal 0.84/
78
0.3 NA Depression. Limb pain. Dyspnea,
palpitations; cardiac catheterization at
age 53Y, with no evidence of CAD.
Family 4
F4:P
(II:5)
F/82 55/ND +/− ND Cerebral small vessel
disease
Yes 16/
ND
Pacemaker
(AV block)
1.7/
28
ND/(uPr =
300 mg/dl)
NA Orthopnea (NYHA, stage 2). Pulmonary
hypertension. Multiple myeloma.
(III:1) F/67 25/ND +/+ ND Parenchymal
changes, possibly
ischemic
NA ND/
ND
Normal 1.02/
57
16 Cataract Hypertension; osteoporosis; colon
cancer.
(III:3) F/60 ND/ND +/+ WT Frontoparietal
subcortical WML
No 9/6 SVT 0.8/
80
2.8 Normal Hypohidrosis. Weakness. Palpitations.
Fibromyalgia.
(III:4) F/51 33/ND +/+ WT Normal No 9/7 WAP 0.6/
106
5.6 Normal Paraesthesias. Palpitations.
Hyperthyroidism.
(IV:1) M/36 83/ND + WT Normal No 9/ND SVPB 0.9/
109
2.2 Normal Angiokeratoma.
P: proband. Gender: male (M)/female (F). Age in years (Y). α-galactosidase A (α-Gal) enzyme activity, as measured in dried blood spots (DBS) or in plasma, is expressed as
percentage (%) of the normal control mean. The molecular data reported for the α-galactosidase A gene (GLA) in each case is the presence of the p.(Arg118Cys)(R118C) variant,
either in hemizygosity (+), heterozygosity (+/−) or homozygosity (+/+), as well as the presence of any of the 5′-untranslated region (5′UTR) polymorphisms that may affect
enzyme expression (−30GNA/−12GNA/10CNT); WT: wild-type 5′UTR sequence. CNS: central nervous system. MRI: magnetic resonance imaging. WML: white matter lesions. LVH: left
ventricular hypertrophy, clinical diagnosis. The interventricular septal thickness (IVS) is expressed in mm, as measured by echocardiography (Echo) / cardiac MRI. Holter monitoring
(24-h)— SVPB: supraventricular premature beats; SVT: supraventricular tachycardia; AV: atrioventricular; WAP: wandering atrial pacemaker. sCr: serum creatinine level, expressed as
mg/dl; eGFR: glomerular ﬁltration rate estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [http://www.kidney.org/professionals/kdoqi/
gfr_calculator.cfm], expressed in ml/min/1.73 m2. UACR: urine albumin-to-creatinine ratio, expressed as mg of albumin per g of creatinine; uPr: urine protein concentration. Eye: ocular
phenotype as described on slit-lamp ophthalmological examination. CAD: coronary artery disease. New York Heart Association (NYHA) functional classiﬁcation of heart failure. ND: not
done/determined; NA: not assessed.
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frequent mutational event, in accordance with its location at a CpG
dinucleotide [39].
4. Discussion
Our data suggest that the GLA p.(Arg118Cys) variant does not segre-
gate with FD manifestations at least in a highly-penetrant Mendelian
fashion. Hemizygous males and homozygous or compound heterozy-
gous femalesmay live at least up to the 8th decade of life, and heterozy-
gous females up to the 9th decade, without developing major organ
complications typical of FD, even in presence of other signiﬁcant car-
diovascular risk factors. These data may explain the absence of FD
history in the Italian family identiﬁed by newborn screening [28]. Sur-
prisingly, carriers of the Cys118 allele may present only with a typical
eruption of angiokeratomas, which is usually considered a manifesta-
tion of classic FD.
The allelic frequency of GLA Cys118 in the Portuguese population is
similar to that reported in North Americans: it can be estimated from
those epidemiological data that in a gender-even cohort of 10.000 indi-
viduals,≈5 males and≈10 females will carry the Cys118 allele, which
is a threefold higher prevalence than the European deﬁnition of “raredisorder” [http://ec.europa.eu/health/ph_threats/non_com/docs/rare_
com_en.pdf]. Furthermore, in a neonatal screening carried out in the
northwest of Spain, 50% of the newbornswith lowplasmaα-Gal activity
in whom missense GLA variants were subsequently identiﬁed were
hemizygous for the GLA Cys118 allele [40].
In the PORTYSTROKE cohort, the GLA p.(Arg.118Cys) and
p.(Asp313Tyr) variants were signiﬁcantly more prevalent than in the
general population; on the other hand, the Cys118 and the Tyr313
hemizygous males had comparable residual plasma α-Gal activities, at
≈40% the normal mean, while their average leukocyte α-Gal activities
were respectively≈35% and≈50% of the normal [29]. These similari-
ties suggest that subnormal α-Gal enzyme activity might be a quantita-
tive, metabolic modulator of the multifactorial risk of cerebrovascular
disease by as yet unknown mechanisms. Recent observations in non-
FD patients have offered some clues as to possible additional links
between human disease and GLA gene expression, α-Gal activity and
Gb3 metabolism: (i) slightly decreased GLA gene expression, leading
to an average reduction of leukocyte α-Gal activity of no more than
≈16.5%, may be a risk factor for sporadic Parkinson disease, possibly
due to dysfunction of the autophagic–lysosomal system [41,42];
(ii) increased urinary Gb3 excretion is independently associated with
the risk of short-term death of patients with common forms of heart
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metabolism in patients with end-stage heart failure, leading to in-
creased incorporation of Gb3 in cell membranes.
Moreover, co-segregation ofGLA variants associatedwith high resid-
ual enzyme activity and the 5′UTR g.1170CNT SNP may have additive
effects, possibly further decreasing the residual enzyme activity even
into the range usually seen in patients with later-onset phenotypic var-
iants of FD. Therefore, screening for the presence of the g.1170CNT SNP
may be helpful for the interpretation of genotype-to-phenotype correla-
tions in patients with such GLA variants. These hypotheses will have to
be conﬁrmed in larger, properly designed studies.
The GLA p.(Arg118Cys) variant was also identiﬁed in the SIFAP
cohort [32], the largest ever FD case-ﬁnding study among stroke
patients (Table 2). As in the Portuguese study, the screening method
was by genotyping, but SIFAP predominantly enrolled patients from
northern and central European countries. Although the Cys118 allele
was regarded as a pathogenic mutation and its presence was a criterion
for deﬁnite diagnosis of FD, the investigators did not provide any con-
vincing evidence to support their assumption. In contrast to the SIFAP
results, GLA p.(Arg118Cys) was not identiﬁed in the Belgian Fabry
Study (BeFaS) [44], which screened a total of 993 adult patients (545
males, 54.9%) presenting with cerebrovascular disease before the age
of 61 years.
One female heterozygous for the GLA Cys118 allele was identiﬁed
in the European Anderson–Fabry Disease Survey [31] (Table 2), a FD
screening study of patients with unexplained HCM. As that woman
alsomanifested angiokeratoma(s?) and albuminuria,GLAp.(Arg118Cys)
was considered pathogenic, but the investigators did not provide
histopathological evidence of FD cardiomyopathy or nephropathy,
and the clinical observation of angiokeratoma(s) is inconclusive,
since the presence of isolated or a few scattered angiokeratomas is
not uncommon in otherwise healthy individuals [45]. In contrast to
these results, the GLA p.(Arg118Cys) variant was not identiﬁed in
any of 279 male patients with HCM screened for FD in a French
case-ﬁnding study [38], neither in any of 508 non-selected patients
(328 males, 64.6%) with HCM screened for FD in a Spanish case-
ﬁnding study [46], using plasma α-Gal activity as the screening
method; however, it is of note that three unrelated men in this co-
hort were hemizygous for the GLA Tyr313 allele.
The GLA p.(Arg118Cys) variant was identiﬁed in two unrelated
males and two sisters, enrolled in a Spanish case-ﬁnding study of
FD among patients with end-stage renal failure (ESRF) on chronic
hemodialysis [30], that used a DBS α-Gal assay as the ﬁrst-tier
screening method. Although the investigators concluded that GLA
p.(Arg118Cys) was a pathogenic mutation, they did not provided
enough evidence to support that claim. The very old age of the two
men precludes the interpretation that their renal, cardiac and cere-
brovascular complications were caused by FD and, for the reason
discussed above, even the presence of angiokeratoma(s?) is not
convincing. In addition to not being clear why the two sisters were
enrolled for GLA genotyping since their α-Gal activities on the DBS
assays were, respectively, 123% and 94% of the female control
mean, they both had human immunodeﬁciency virus (HIV) infec-
tion that more probably was the cause of their kidney disease. Fur-
thermore, a kidney biopsy from the younger sister reportedly
showed glomerulosclerosis and hyalinosis, but did not show the
most typical LM feature of Fabry nephropathy (e.g. vacuolation).
While glomerulosclerosis and hyalinosis are possible manifestations
of HIV-associated nephropathy, in Caucasians immune-complex-
mediated kidney injury is much more common due to the absence
of the ApoL1 polymorphisms associated with HIV nephropathy. Of
note, the investigators classiﬁed the GLA p.(Asp313Tyr) SNP, that
was found in an 80-year-old female and a 74-year-old male, as a se-
quence variant of controversial pathogenicity. Apparently in line
with these observations, one Cys118 hemizygous male enrolled in
the Fabry Registry [47] started dialysis at age 45 years.In contrast to those Spanish data, neither the p.(Arg118Cys) nor the
p.(Asp313Tyr) GLA variants were identiﬁed in the 2688men enrolled in
the Portuguese screening of FD among non-selected dialysis patients
[48]. Although the Portuguese investigators also used a DBS α-Gal
assay for case ﬁnding, the b30% cut-off level of residual enzyme activity
to proceed with further diagnostic tests (unpublished data) was more
stringent than in the Spanish study, and patients showing high residual
enzyme activities, in the range observed in hemizygous males for GLA
p.(Arg118Cys) or p.(Asp313Tyr), would not be selected for genotyping.
Overall, those studies demonstrate that the identiﬁcation of GLA
variants associated with residual α-Gal activity on large cohorts will
critically depend on the screeningmethod used and, when based on en-
zyme assays, on the predeﬁned cut-off level of residual enzyme activity
to select cases for genotyping.
It should be noted, however, that the correlations between the
in vitro α-Gal residual activity, substrate accumulation and the FD
clinical phenotype are complex and still incompletely understood, and
that other factors, besides the residual level of enzyme activity, play a
crucial role in the pathogenesis of the disease [49]. It might also be
possible that the in vitro α-Gal assays do not reﬂect the biological
enzyme activity in vivo, thereby confounding the interpretation of
genotype-phenotype correlations.
Because of the non-speciﬁc features of the late-onset cerebro-
vascular, cardiac and renal complications of FD, and the much higher
prevalence of other causes of stroke, LVH/HCM and ESRF in adult popu-
lations, FD case-ﬁnding studies among high-risk patients are intrinsical-
ly biased. Accordingly, reports of patients identiﬁed in such studies,
carrying either novel GLA sequence variants or VUS, particularly when
associated with high residual α-Gal activity, should provide enough
clinical, biochemical and histopathological details to support the diag-
nosis of FD, and exclude the relevant differential diagnoses, on a case-
by-case basis. This same approach has been recently recommended by
Dutch experts on FD [50]. Furthermore, proper assessment of the
medical relevance of newly identiﬁed GLA sequence variants or VUS
should also take into consideration the genetic makeup of the source
populations, but the relevant allelic frequencies will have to be estimat-
ed in studies large enough to identify low-frequency (MAF between
0.05–0.005) and rare variants (MAF b 0.005), which vastly outnumber
the common variants in the human genome and show substantial
geographic differentiation [51,52]. Although the country of origin of
the patient(s) carrying the p.(Arg118Cys) allele identiﬁed in the SIFAP
and EAFDS studies was not reported, it appears from the published
data that the allelic frequency of p.(Arg118Cys) is signiﬁcantly lower
in northern and central European countries than in the Iberian
populations.
The assumption that GLA p.(Arg118Cys) is a pathogenic mutation
causing a later-onset FD phenotype [28] was based on theoretical
considerations about the similarities of the structural changes it induces
in the α-Gal monomer and of its in vitro overexpression levels,
with those of well-known missense GLA mutations associated with
later-onset clinical phenotypes, as well as on the reasoning that its
sulfhydryl-binding potential might interfere with the normal disulﬁde
bonds of the α-Gal monomers. In our opinion, which is instead based
upon detailed and unbiased clinical, biochemical, histopathological
and family data, the mild/moderate deﬁciency of α-Gal activity associ-
ated with p.(Arg118Cys) is not of enough magnitude to cause major
complications of FD and, therefore, carriers of the Cys118 allele current-
ly have no straightforward indication for enzyme replacement or
enhancement (chaperone) therapy. Despite involving a cysteine
residue, GLA p.(Arg118Cys) most likely is a non-pathogenic or of
low-pathogenicity exonic variant, like p.(Asp313Tyr) and a few
others [50]. A notable example of another GLA variant whose alleged
pathogenic role has recently been questioned [53] is the guanine to
adenine transition (GNA) in codon 143 (c.427GNA), resulting in
the replacement of alanine (Ala) by threonine (Thr) in the α-Gal
monomers — i.e., p.(Ala143Thr). Although hemizygous males for
257S. Ferreira et al. / Molecular Genetics and Metabolism 114 (2015) 248–258the GLA Thr143 allele may variably show undetectable to moderately
reducedα-Gal activity in vitro, the previously reported association of
this variant with renal failure, stroke, and LVH could be the result of
selection bias. Indeed, most of those cases were detected in screen-
ings of high-risk patients, in whom histopathological or ultrastruc-
tural evidence of Gb3 accumulation in affected tissues was not
speciﬁcally investigated [53].
Finally, the observation that the estimated prevalence of individuals
carrying the GLA Cys118 allele in the Portuguese population is higher
than current deﬁnitions of “rare diseases”, should have regulatory
implications for the inclusion of such individuals in therapeutic drug
trials for FD.
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